The Charcot-Marie-Tooth Disease Type I drugs in development market research report provides comprehensive information on the therapeutics under development for Charcot-Marie-Tooth Disease Type I, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Charcot-Marie-Tooth Disease Type I. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Charcot-Marie-Tooth Disease Type I and features dormant and discontinued products.
GlobalData tracks 28 drugs in development for Charcot-Marie-Tooth Disease Type I by 25 companies/universities/institutes. The top development phase for Charcot-Marie-Tooth Disease Type I is preclinical with 15 drugs in that stage. The Charcot-Marie-Tooth Disease Type I pipeline has 26 drugs in development by companies and two by universities/ institutes. Some of the companies in the Charcot-Marie-Tooth Disease Type I pipeline products market are: NMD Pharma, Armatus Bio and Samsara Therapeutics.
The key targets in the Charcot-Marie-Tooth Disease Type I pipeline products market include Peripheral Myelin Protein 22, Gamma-Aminobutyric Acid Type B Receptor Subunit, and Histone Deacetylase 6.
The key mechanisms of action in the Charcot-Marie-Tooth Disease Type I pipeline product include Peripheral Myelin Protein 22 Inhibitor with ten drugs in Preclinical. The Charcot-Marie-Tooth Disease Type I pipeline products include four routes of administration with the top ROA being Oral and six key molecule types in the Charcot-Marie-Tooth Disease Type I pipeline products market including Small Molecule, and Gene Therapy.
Charcot-Marie-Tooth Disease Type I overview
Charcot-Marie-Tooth disease, a group of hereditary sensory and motor neuropathies affecting peripheral nerves, leads to progressive damage connecting the brain and spinal cord to muscles and sensory cells. Manifesting in adolescence or adulthood, it causes sensation alteration, muscle wasting, and varying physical disabilities. Initial symptoms involve muscle atrophy in the feet, often accompanied by foot abnormalities, and difficulties in flexing or walking on the heels. As the disease advances, leg and hand weakness emerges, impacting daily activities. Sensory loss, decreased touch sensitivity, and occasional burning sensations follow. Subtypes like CMT1, characterized by myelin abnormalities, and CMT2, affecting nerve fibers, distinguish patterns of inheritance and manifestations. CMT1A is caused by having an extra copy (a duplication) of the PMP22 gene. Historical names, such as Roussy-Levy syndrome and Dejerine-Sottas syndrome, highlight additional features or early-onset severity in certain forms of the disease.
For a complete picture of Charcot-Marie-Tooth Disease Type I’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
